Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Aurora CannabisACB -0.56%57 Earnings Yield (Joel Greenblatt) % is -30.96% as of Mar. 2026. GuruFocus rates ACB with a GF Score™ of 57/100 and a GF Value™ of $4.20 (Possible Value Trap). The stock has 2 warning signs investors should review. Among 1,011 Drug Manufacturers companies, Aurora Cannabis ranks worse than 93.77% on this metric.
Aurora Cannabis's Enterprise Value for the quarter that ended in Mar. 2026 was $124.9 Mil.
Aurora Cannabis's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 was $-39.7 Mil. Aurora Cannabis's Earnings Yield (Joel Greenblatt) for the quarter that ended in Mar. 2026 was -30.96%.
The historical rank and industry rank for Aurora Cannabis's Earnings Yield (Joel Greenblatt) % or its related term are showing as below:
ACB'
s Earnings Yield (Joel Greenblatt) % Range Over the Past 10 Years
Min: -696.41 Med: -9.77 Max: 10.67
Current: -38.91
During the past 13 years, the highest Earnings Yield (Joel Greenblatt) of Aurora Cannabis was 10.67%. The lowest was -696.41%. And the median was -9.77%.
ACB's Earnings Yield (Joel Greenblatt) % is ranked worse than 93.77% of 1011
companies
in the Drug Manufacturers industry
Industry Median: 3.31
vs ACB: -38.91
Joel Greenblatt's definition of earnings yield has the same problems the regular earnings yield does. It does not consider the growth of the company. It only looks at one-year's business operation. For cyclical companies, the earnings yield is usually highest at the peak of the business cycle. But these earnings are rarely sustainable.
A better indicator of the attractiveness of an investment which takes growth into account is the Forward Rate of Return (Yacktman) %. Aurora Cannabis's Forward Rate of Return (Yacktman) % for the quarter that ended in Mar. 2026 was 0.00%. The Forward Rate of Return uses the normalized Free Cash Flow of the past five years, and considers growth. The forward rate of return can be thought of as the return that investors buying the stock today can expect from it in the future.
Joel Greenblatt defines the earnings yield using the above equation because it more accurately reflects the company's profitability relative to its stock price. Items like interest payment and tax etc. are not directly related to the company's operational profitability.
Enterprise Value instead of market cap (share price) is used in the calculation because it is the real price stock and bond investors together pay for the company.
Be Aware
Joel Greenblatt's definition of earnings yield has the same problems the regular earnings yield does. It does not consider the growth of the company. It only looks at one-year's business operation. For cyclical companies, the earnings yield is usually highest at the peak of the business cycle. But these earnings are rarely sustainable.
Aurora Cannabis Earnings Yield (Joel Greenblatt) % Related Terms
Aurora Cannabis Earnings Yield (Joel Greenblatt) % Historical Data
* Premium members only.
The historical data trend for Aurora Cannabis's Earnings Yield (Joel Greenblatt) % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ACB vs ZTS, UTHR: Earnings Yield (Joel Greenblatt) % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Aurora Cannabis's Earnings Yield (Joel Greenblatt) %, along with its competitors' market caps and Earnings Yield (Joel Greenblatt) % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Aurora Cannabis Earnings Yield (Joel Greenblatt) % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Aurora Cannabis's Earnings Yield (Joel Greenblatt) % distribution charts can be found below:
* The bar in red indicates where Aurora Cannabis's Earnings Yield (Joel Greenblatt) % falls into.
In his book, The Little That Beat the Market, hedge fund manager Joel Greenblatt defines Earnings Yield as operating income divided by enterprise value.
Aurora Cannabiss Earnings Yield (Joel Greenblatt) for the fiscal year that ended in Mar. 2026 is calculated as
Aurora Cannabis's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-39.7 Mil.
What does a Earnings Yield (Joel Greenblatt) % of -30.96% mean?
Aurora Cannabis (ACB) has a Earnings Yield (Joel Greenblatt) % of -30.96% as of Mar. 2026. Joel Greenblatt's earnings yield equals the ratio of earnings before interest and taxes to enterprise value. View historical data on Aurora Cannabis and its competitors. According to the industry distribution chart, Aurora Cannabis ranks #948 out of 1011 companies in the Drug Manufacturers industry, placing it in the top 93.8%.
Is Aurora Cannabis' Earnings Yield (Joel Greenblatt) % too high?
Aurora Cannabis' current Earnings Yield (Joel Greenblatt) % is -30.96%. Based on the distribution chart, Aurora Cannabis ranks #948 out of 1011 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Aurora Cannabis has a GF Score™ of 57/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Aurora Cannabis' Earnings Yield (Joel Greenblatt) % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Aurora Cannabis ranks #948 out of 1011 companies for Earnings Yield (Joel Greenblatt) %. This places Aurora Cannabis in the lower half of its industry. The industry median Earnings Yield (Joel Greenblatt) % is 3.31. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Earnings Yield (Joel Greenblatt) % for a Drug Manufacturers company?
The median Earnings Yield (Joel Greenblatt) % among Drug Manufacturers companies is 3.31, based on 1,011 companies in the industry. Companies in the top quartile (top 25%) have a Earnings Yield (Joel Greenblatt) % significantly above this median, while those in the bottom quartile fall well below. However, Earnings Yield (Joel Greenblatt) % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Earnings Yield (Joel Greenblatt) % mean?
A high Earnings Yield (Joel Greenblatt) % can signal that a stock is expensive relative to its fundamentals. Joel Greenblatt's earnings yield equals the ratio of earnings before interest and taxes to enterprise value. View historical data on Aurora Cannabis and its competitors. For the Drug Manufacturers industry, the median Earnings Yield (Joel Greenblatt) % is 3.31 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Aurora Cannabis's current Earnings Yield (Joel Greenblatt) % is -30.96%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Aurora Cannabis stock overvalued right now?
Based on GuruFocus' analysis, Aurora Cannabis (ACB) is currently considered Possible Value Trap. The stock's GF Value™ is $4.20, compared to a current price of $2.68 — trading 36.2% below its estimated fair value. The current Earnings Yield (Joel Greenblatt) % is -30.96%. Aurora Cannabis' overall GF Score™ is 57/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Earnings Yield (Joel Greenblatt) % calculated?
Earnings Yield (Joel Greenblatt) % is calculated from a company's financial statements. For Aurora Cannabis (ACB), the current Earnings Yield (Joel Greenblatt) % is -30.96% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Aurora Cannabis (ACB) Overvalued in 2026?
Based on GuruFocus' analysis, Aurora Cannabis stock appears to be undervalued.
The current stock price of $2.68 is trading 36.2% below its estimated GF Value™ of $4.20.
GuruFocus considers Aurora Cannabis to be Possible Value Trap.
Key valuation signals for ACB:
Earnings Yield (Joel Greenblatt) %: -30.96%
GF Value™: $4.20 vs. price of $2.68 (36.2% below fair value)
No single metric tells the full story. See the ACB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Aurora Cannabis Inc is focused on the production, distribution, and sale of cannabis products in Canada and internationally. The Company conducts the production, distribution, and sale of medical cannabis products and, on a very limited basis, consumer cannabis products in Canada pursuant to the Cannabis Act; the production and distribution of wholesale medical cannabis in the European Union pursuant to the German Medicinal Products Act and German Narcotic Drugs Act; and the distribution of wholesale medical cannabis in various international markets, including Australia and New Zealand. Its segments are Canadian Cannabis CGU, European Cannabis CGU, Australia Cannabis CGU, and New Zealand Cannabis CGU, with Canada generating majority revenue.
57GF Score
Get the complete analysis for ACB
Earnings Yield (Joel Greenblatt) % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ACB has been successfully added to your 
